Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

JCO Early Release, published online ahead of print Nov 2 2009
Journal of Clinical Oncology, 10.1200/JCO.2009.24.2222

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Winer, E. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Winer, E. P.
Related Articles
Right arrowRelated Articles
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Refining Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy

Harold J. Burstein and Eric P. Winer

Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Articles

  • Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
    Heikki Joensuu, Petri Bono, Vesa Kataja, Tuomo Alanko, Riitta Kokko, Raija Asola, Tapio Utriainen, Taina Turpeenniemi-Hujanen, Sirkku Jyrkkiö, Kari Möykkynen, Leena Helle, Seija Ingalsuo, Marjo Pajunen, Mauri Huusko, Tapio Salminen, Päivi Auvinen, Hannu Leinonen, Mika Leinonen, Jorma Isola, and Pirkko-Liisa Kellokumpu-Lehtinen
    JCO 2009 27: 5685-5692 [Abstract] [Full Text]
  • Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
    Giuseppe Curigliano, Giuseppe Viale, Vincenzo Bagnardi, Luca Fumagalli, Marzia Locatelli, Nicole Rotmensz, Raffaella Ghisini, Marco Colleoni, Elisabetta Munzone, Paolo Veronesi, Stefano Zurrida, Franco Nolè, and Aron Goldhirsch
    JCO 2009 27: 5693-5699 [Abstract] [Full Text]
  • Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
    Neil L. Spector and Kimberly L. Blackwell
    JCO 2009 27: 5838-5847 [Abstract] [Full Text]
  • High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller
    Ana M. Gonzalez-Angulo, Jennifer K. Litton, Kristine R. Broglio, Funda Meric-Bernstam, Ronjay Rakkhit, Fatima Cardoso, Florentia Peintinger, Emer O. Hanrahan, Aysegul Sahin, Merih Guray, Denis Larsimont, Francesco Feoli, Heidi Stranzl, Thomas A. Buchholz, Vicente Valero, Richard Theriault, Martine Piccart-Gebhart, Peter M. Ravdin, Donald A. Berry, and Gabriel N. Hortobagyi
    JCO 2009 27: 5700-5706 [Abstract] [Full Text]




About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online